You are here

Structural Heart

 

Approximately 91 percent of patients with primary mitral regurgitation had procedural success after undergoing transcatheter mitral valve repair with the MitraClip, according to a registry analysis. The researchers defined procedural success as a reduction to moderate or less mitral regurgitation in the absence of cardiac surgery or in-hospital mortality.

 

 

Recent Headlines

Strong TAVR sales help Edwards Lifesciences increase revenue in first quarter

Led by a 37 percent increase in its transcatheter heart valve sales, Edwards Lifesciences reported on April 26 that its revenue increased 18.1 percent and its earnings per share increased 17.9 percent during the first quarter of 2016.

Medtronic enrolls first patients in CoreValve Evolut R trial for expanded FDA indication

Medtronic announced on March 31 that the first patients had enrolled in an expanded indication trial for the CoreValve Evolut R System, a device for transcatheter aortic valve replacement (TAVR) procedures. The FDA approved the CoreValve Evolut R System in June 2015 to treat patients with severe aortic stenosis.

FDA approves two studies examining TAVR devices

The FDA recently approved two investigational device exemption trials that will examine devices for patients undergoing transcatheter aortic valve replacement (TAVR).

Registry analysis finds 91% of patients receiving the MitraClip have procedural success

Approximately 91 percent of patients with primary mitral regurgitation had procedural success after undergoing transcatheter mitral valve repair with the MitraClip, according to a registry analysis. The researchers defined procedural success as a reduction to moderate or less mitral regurgitation in the absence of cardiac surgery or in-hospital mortality.

Game Changer: Success Positions TAVR for Expanded Indications

Transcatheter aortic valve replacement (TAVR) is proving to be a disruptive technology, as cardiac surgeons and cardiologists join forces and combine resources to determine its ultimate utility.

Abbott initiates voluntary MitraClip delivery system safety notice

Abbott initiated a voluntary safety notice on Feb. 26 regarding its MitraClip delivery system. Although the FDA classified the notice as a Class I recall, Abbott is not removing any products from commercial distribution.

Women have lower one-year mortality rates after TAVR with the Sapien valve

Women undergoing transcatheter aortic valve replacement (TAVR) had a lower mortality rate one year after the procedure compared with men, according to a secondary analysis of the PARTNER (Placement of Aortic Transcatheter Valves) trial.

Mended Hearts launches LVAD video contest

Mended Hearts, a heart patient support network, launched a video contest on Feb. 18 for people who have received a left ventricular assist device (LVAD) to treat heart failure.

ACC announces late-breaking clinical trials for annual scientific session

The American College of Cardiology (ACC) announced the late-breaking clinical trials sessions for its 65th annual scientific session. The conference is taking place from April 2 to 4 at the McCormick Place convention center in Chicago.

Edwards Lifesciences’ TAVR sales increase 25 percent in fourth quarter

Led by strong sales in its transcatheter heart valve therapy (THV) division, Edwards Lifesciences’ fourth quarter revenue in 2015 increased 8.6 percent and its GAAP earnings per share increased 28.0 percent compared with the same period a year earlier.

Pages